Open AccessMitigation of 2,4-dinitrofluorobenzene-induced atopic dermatitis-related symptoms by Terminalia chebula Retzius
Author(s) -
SangHan Lee
Publication year - 2011
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2011.792
Subject(s) - terminalia chebula , atopic dermatitis , terminalia , eosinophil , h&e stain , immunology , in vivo , atopy , matrix metalloproteinase , medicine , traditional medicine , pharmacology , allergy , biology , immunohistochemistry , microbiology and biotechnology , asthma
To evaluate whether an aqueous seed extract of Terminalia chebula Retzius inhibited development of atopy in vivo, we used a 2,4-dinitrofluorobenzene (DNFB)-induced animal model of atopic symptoms to investigate the effects of the extract. We measured CD4+ cell numbers by hematoxylin and eosin (H&E) staining, and determined the expression levels of matrix metalloproteinase (MMP)-9, interleukin (IL)-31, and T-bet genes, in this animal model. The data showed that a Terminalia chebula extract (100 µg/ml) exhibited strong anti-atopic activity, mediating a 52% reduction in the immune response, as measured by thickness of ear swelling, and resulting in decreased eosinophil levels in adjacent skin tissue. Collectively, the results indicate that a Terminalia chebula seed extract has potential for alleviation of atopy-like symptoms induced by DNFB in the mouse.